DDInter481 DDInter1435
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voriconazole
Darolutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Larotrectinib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Niraparib
Darolutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eslicarbazepine
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Eluxadoline
Darolutamide {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Voriconazole
Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Darolutamide may lead to a major life threatening interaction when taken with Eluxadoline
Darolutamide may lead to a major life threatening interaction when taken with Berotralstat